A screening for latent tuberculosis infection among candidates to anti-tumor necrosis factor-alpha agents using a whole blood interferon-gamma test Source: Annual Congress 2008 - Interferon-gamma release assay tests for diagnosing tuberculosis infection and disease Year: 2008
Implication of leptin, tumor necrosis factor-alpha, interleukin-1 and interleukin-6 in the pathogenesis of wasting in tuberculosis Source: Annual Congress 2006 - Immunology of tuberculosis and diagnosis of tuberculosis infection Year: 2006
Re-activation of bovine tuberculosis in a patient treated with infliximab Source: Eur Respir J 2008; 32: 229-231 Year: 2008
Evaluation levels of pro-inflammatory cytokines tumour necrosis factor (TNF)-alpha and interferon (IFN)-gamma in lung cancer complicated with metastatic pleurisy Source: Eur Respir J 2001; 18: Suppl. 33, 233s Year: 2001
Tumor necrosis factor alpha inhibitors and reactivation of tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 281s Year: 2007
Changes in the quantity of 1b-interleukin (IL-1b), tumor necrosis factor-a (TNF-a) and interferon-g (IF-g) in evaluation of the effectiveness of treatment of tuberculosis by DOTS Source: Eur Respir J 2004; 24: Suppl. 48, 486s Year: 2004
Screening for latent tuberculosis before tumour necrosis factor antagonist therapy Source: Eur Respir J 2015; 45: 1510-1512 Year: 2015
Screening for latent tuberculosis before tumour necrosis factor antagonist therapy Source: Eur Respir J 2015; 45: 1512-1513 Year: 2015
Effects of zinc on the interleukin-1 and tumor necrosis factor in experimental silicosis Source: Eur Respir J 2002; 20: Suppl. 38, 517s Year: 2002
Mycobacterial diseases developed during anti-tumour necrosis factor alpha therapy Source: Eur Respir J 2014; 44: 1289-1295 Year: 2014
Evaluation levels of pro-inflammatory cytokines tumour necrosis factor (TNF)-alpha and interleukin (IL) 1-beta in small cell lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 233s Year: 2001
Screening and monitoring of tuberculosis in patients on tumor necrosis factor antagonist therapy Source: Annual Congress 2011 - Clinical challenges in tuberculosis Year: 2011
Isoniazid protection and risk of tuberculosis in patients who used anti tumor necrosis factor-alpha treatment Source: Annual Congress 2007 - New perspectives and old problems in diagnosing tuberculosis infection and disease Year: 2007
Association of the TNF gene promoter polymorphism with serum tumor necrosis factor-alpha levels in chronic obstructive pulmonary disease patients Source: Eur Respir J 2006; 28: Suppl. 50, 522s Year: 2006
Levels of plasma tumour necrosis factor and soluble tumour necrosis factor receptor in patients with COPD and its relation to glucocorticoid receptor levels Source: Annual Congress 2009 - Biomarkers and biology in COPD Year: 2009
Tumor necrosis factor-α and interleukin-6 gene polymorphisms in pulmonary embolism Source: Eur Respir J 2005; 26: Suppl. 49, 520s Year: 2005
Using an interferon-γ assay for the diagnosis of tuberculosis infection before using tumor necrosis factor-α blockers Source: Annual Congress 2007 - Gamma-interferon-based tests to diagnose tuberculosis infection and disease Year: 2007
Does tumor necrosis factor-alpha increase oxidative stress in bronchial asthma? Source: Eur Respir J 2003; 22: Suppl. 45, 111s Year: 2003
The risk of tuberculosis related to tumour necrosis factor antagonist therapies Source: Annual Congress 2011 - TBNET: tuberculosis research in Europe Year: 2011
The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement Source: Eur Respir J 2010; 36: 1185-1206 Year: 2010